To: AmeriHealth Caritas DC Providers  
Date: November 16, 2017  
Subject: Changes to Opioid Dependence Agents

Summary: Effective October 16, 2017 Buprenorphine/Naloxone tablets are available as preferred agents, for dosing of up to 24mg per day with specific quantity limits applied to the various strengths.

Impact
This is a communication to alert you that AmeriHealth Caritas District of Columbia has made some changes to the Opioid Dependence agents on the formulary.

Effective October 16, 2017 Buprenorphine/Naloxone tablets are available as preferred agents, for dosing of up to 24mg per day with specific quantity limits applied to the various strengths. (See quantity limit restriction list below.) Dosing greater than 24mg per day will still require a prior authorization request be submitted, which will be reviewed against the current criteria for Opioid Dependence agents.

Quantity Limit restrictions for Preferred Opioid Dependence agents

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Buprenorphine/Naloxone 2mg tablets</td>
<td>Quantity limit of 4 tablets a day</td>
</tr>
<tr>
<td>Buprenorphine/Naloxone 8mg tablets</td>
<td>Quantity limit of 3 tablets a day</td>
</tr>
</tbody>
</table>

Action
Other opioid dependence agents, such as Suboxone sublingual film, Buprenorphine tablets, Zubsolv tablets, Bunavail or any other newly marketed agent for opioid dependence, are still non-preferred and must be prior authorized.

Questions
If you have any questions about this communication, please contact Tracey Davis, PharmD, Director of Pharmacy at 202-349-3578.